Prescription medicines
Astellas develops and sells branded prescription drugs for use in hospitals, clinics, and pharmacies, with products in urology, oncology, immunology and transplant care, and eye care.
Customers and revenue model
Astellas Pharma Inc
F:YPHA
Astellas Pharma Inc
F:YPHA
Price:
14.6
EUR
6.57%
Market Closed
Market Cap:
€26.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Astellas Pharma Inc
F:YPHA
|
JP |
|
D
|
Dollarama Inc
SWB:DR3
|
CA |
|
D
|
Duke Energy Corp
XHAM:D2MN
|
US |
|
D
|
DRDGOLD Ltd
SWB:DUBA
|
ZA |
|
B
|
BROOKFIELD ASSET MANAGEMENT LTD
TSX:BAM
|
CA |
|
V
|
Volati AB
LSE:0RKK
|
SE |
|
S
|
Steelcase Inc
SWB:GJB
|
US |
|
S
|
Sula Vineyards Ltd
BSE:543711
|
IN |
|
SRP Groupe SA
PAR:SRP
|
FR |
|
T
|
Telix Pharmaceuticals Ltd
OTC:TLPPF
|
AU |
|
M
|
Microstrategy Inc
SWB:MIGA
|
US |
|
G
|
Grupo Aeroportuario del Sureste SAB de CV
SWB:AED
|
MX |
|
Vardhman Textiles Ltd
NSE:VTL
|
IN |
|
Fubon Financial Holding Co Ltd
TWSE:2881
|
TW |
|
C
|
Constellium SE
XMUN:3OK
|
FR |
|
O
|
Omni-Lite Industries Canada Inc
OTC:OLNCF
|
US |
|
O
|
OSE Immunotherapeutics SA
LSE:0RAD
|
FR |
|
Garware Hi-Tech Films Ltd
BSE:500655
|
IN |
|
T
|
Ternium SA
SWB:T5Z
|
LU |
|
Focus Universal Inc
NASDAQ:FCUV
|
US |
|
C
|
Caxton and CTP Publishers and Printers Ltd
JSE:CAT
|
ZA |
|
Megaport Ltd
ASX:MP1
|
AU |
|
R
|
RWE AG
F:RWEA
|
DE |
|
Z
|
Zhong An Group Ltd
HKEX:672
|
CN |
Company Overview
Business Description
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Headquarters
- Japan JP
- Employees
- 13 643
- IPO date
- May 16, 1949
Astellas Pharma is a Japanese drug company that discovers, develops, makes, and sells prescription medicines. Its main products treat areas such as urology, transplant medicine, immunology, cancer, and eye disease. The company spends heavily on research and then brings branded drugs through testing, approval, manufacturing, and distribution.
Its main customers are doctors, hospitals, pharmacies, and healthcare systems that prescribe or buy medicines for patients. Astellas makes money mostly by selling prescription drugs, along with income from licensing and partnership deals when it shares technology or rights to certain medicines with other drugmakers.
What makes Astellas different is that it sits in the high-value part of the pharmaceutical chain: it turns scientific research into approved medicines for specific diseases. That means its business depends less on high-volume commodity sales and more on a smaller number of branded treatments that are protected by patents and supported by medical data.
Continue YPHA Research
Other Astellas Pharma Inc listings:
